-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on BioCryst Pharma, Maintains $16 Price Target

Benzinga·09/08/2026 17:33:05
Listen to the news
Needham analyst Serge Belanger reiterates BioCryst Pharma (NASDAQ:BCRX) with a Buy and maintains $16 price target.